Evidence map›Paper›PMID 39520155›Full record

ReviewAllergy2025

Biologics and airway remodeling in asthma: early, late, and potential preventive effects.

G Varricchi, R Poto, M Lommatzsch, G Brusselle, F Braido, J C Virchow, G W Canonica

Abstract readReview
In one paragraph

Review in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Vascular remodeling in asthma: from mechanisms to precision medicine.Current opinion in allergy and clinical immunology · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Astragalus polysaccharide mitigates the airway inflammation in bronchial asthma by regulating Hedgehog/NLRP3/GSDMD pathway.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

G VarricchiDepartment of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.ORCID 0000-0002-9285-4657
R PotoDepartment of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.ORCID 0000-0002-4723-0167
M LommatzschDepartment of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.ORCID 0000-0002-9305-9348
G BrusselleDepartment of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
F BraidoRespiratory Diseases and Allergy Department, IRCCS Polyclinic Hospital San Martino, Genoa, Italy.
J C VirchowDepartment of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.ORCID 0000-0003-4291-1956
G W CanonicaRespiratory Diseases and Allergy Department, IRCCS Polyclinic Hospital San Martino, Genoa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although airway remodeling in severe and/or fatal asthma is still considered irreversible, its individual components as a cause of clinical symptoms and/or lung function changes remain largely unknown. While inhaled glucocorticoids have not consistently been shown to affect airway remodeling, biologics targeting specific pathways of airway inflammation have been shown to improve lung function, mucus plugging, and airway structural changes that can exceed those seen with glucocorticoids. This superiority of biologic treatment, which cannot be solely explained by insufficient doses or limited durations of glucocorticoid therapies, needs to be further explored. For this field of research, we propose a novel classification of the potential effects of biologics on airway remodeling into three temporal effects: early effects (days to weeks, primarily modulating inflammatory processes), late effects (months to years, predominantly affecting structural changes), and potential preventive effects (outcomes of early treatment with biologics). For the identification of potential preventive effects of biologics, we call for studies exploring the impact of early biological treatment on airway remodeling in patients with moderate-to-severe asthma, which should be accompanied by a long-term evaluation of clinical parameters, biomarkers, treatment burden, and socioeconomic implications.

Indexed as

Airway RemodelingAnti-Asthmatic AgentsAsthmaBiological ProductsBiomarkersHumansTreatment OutcomeAnti-Asthmatic AgentsBiological ProductsBiomarkersasthma treatmentbiologicsremodeling

Identifiers

PMID39520155
PMCPMC11804314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.